Skip to main content

Featured

Xu Bing named cultural ambassador

Secretary for Culture, Sports & Tourism Kevin Yeung has appointed Chinese contemporary artist Xu Bing as Ambassador for Cultural Promotion for about five years starting today.    As Ambassador for Cultural Promotion, Mr Xu will initiate a series of large-scale art projects in Hong Kong and nurture young talent to promote cultural development.   The Culture, Sports & Tourism Bureau said the appointment aims to extend the Ambassador for Cultural Promotion scheme to other fields of arts, after Chinese composer, musician and conductor Tan Dun became Hong Kong’s first Ambassador for Cultural Promotion last year.   Speaking at the appointment ceremony today, Mr Yeung said Mr Xu is widely recognised as one of the most innovative and influential Chinese contemporary artists.   The culture chief added that the Museum of Art collected one of Mr Xu's most well-known works A Book from the Sky, which contains both traditional and contemporary elements, just like Hong Kong

Vaccine recommendations published

The two scientific committees under the Centre for Health Protection convened a meeting today to provide recommendations on the use of COVID-19 vaccination for those with previous COVID-19 infection.   Joined by the Chief Executive’s expert advisory panel, the committees also discussed the existing evidence on COVID-19 vaccine effectiveness against different variants.       The meeting noted that previous COVID-19 infection usually confers immunity for at least six to nine months for the majority of patients. There is accumulating evidence showing that those previously infected with COVID-19 would be further protected by one dose of mRNA vaccines.   After receiving one dose of mRNA vaccine, these people may experience more systemic side effects, such as fatigue, headache, chills, muscle pain, fever and joint pain, when compared to those without prior infection.   People who wish to receive the mRNA vaccine should wait for at least 90 days after discharge from previous infection.   The meeting also noted that in general, studies have shown that the existing vaccines work well against the non-variant. The effectiveness data against variants differ by vaccines.   The Fosun Pharma/BioNTech vaccine is effective against the variants which first emerged in the UK and Brazil, but is less effective against the South African one.   There is currently limited efficacy data of CoronaVac developed by Sinovac Biotech (Hong Kong) against variants.   The vaccine developed by AstraZeneca in collaboration with the University of Oxford is effective against the UK variants but is ineffective against the South African one.   The meeting also agreed that the combination of non-pharmaceutical interventions with vaccination will allow for maximum protection against the virus. There is a need to continue social distancing, good hand hygiene and wearing a mask in public to reduce the risk of transmission.
http://dlvr.it/RvxspP

Popular Posts